306 related articles for article (PubMed ID: 33256590)
21. [Periprocedural edoxaban interruption is associated with low bleeding and thromboembolic risk: the Italian data of the EMIT-AF/VTE study].
Fazio G; Squizzato A; Mazzetti M; Mannarini A; Fischetti A; Colonna P
G Ital Cardiol (Rome); 2021 Jan; 22(1):70-79. PubMed ID: 33470246
[TBL] [Abstract][Full Text] [Related]
22. Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives.
Blann AD; Boriani G; Lip GY
Europace; 2016 Oct; 18(10):1507-1513. PubMed ID: 27876695
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial.
Wilkinson C; Wu J; Searle SD; Todd O; Hall M; Kunadian V; Clegg A; Rockwood K; Gale CP
BMC Med; 2020 Dec; 18(1):401. PubMed ID: 33357217
[TBL] [Abstract][Full Text] [Related]
24. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
[TBL] [Abstract][Full Text] [Related]
25. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
Miyamoto S; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Murakawa Y; Iwashiro S; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104584. PubMed ID: 31983518
[TBL] [Abstract][Full Text] [Related]
26. Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.
Wang K; Li H; Kwong WJ; Antman EM; Ruff CT; Giugliano RP; Cohen DJ; Magnuson EA;
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862934
[TBL] [Abstract][Full Text] [Related]
27. Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT-AF/VTE)-Trial design.
Colonna P; von Heymann C; Santamaria A; Matsushita Y; Unverdorben M
Clin Cardiol; 2018 Sep; 41(9):1123-1129. PubMed ID: 30069910
[TBL] [Abstract][Full Text] [Related]
28. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
[TBL] [Abstract][Full Text] [Related]
29. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.
Carnicelli AP; De Caterina R; Halperin JL; Renda G; Ruff CT; Trevisan M; Nordio F; Mercuri MF; Antman E; Giugliano RP;
Circulation; 2017 Mar; 135(13):1273-1275. PubMed ID: 28209729
[No Abstract] [Full Text] [Related]
30. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.
Berg DD; Ruff CT; Jarolim P; Giugliano RP; Nordio F; Lanz HJ; Mercuri MF; Antman EM; Braunwald E; Morrow DA
Circulation; 2019 Feb; 139(6):760-771. PubMed ID: 30586727
[TBL] [Abstract][Full Text] [Related]
31. Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients.
Schäfer A; Flierl U; Berliner D; Bauersachs J
Cardiovasc Drugs Ther; 2020 Aug; 34(4):555-568. PubMed ID: 32350792
[TBL] [Abstract][Full Text] [Related]
32. Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial.
Steffel J; Ruff CT; Braunwald E; Hamershock RA; Murphy SA; Nieminen M; Lanz HJ; Mercuri MF; Peterson N; Antman EM; Giugliano RP
Europace; 2019 Feb; 21(2):306-312. PubMed ID: 30462220
[TBL] [Abstract][Full Text] [Related]
33. Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score-Matched Study.
Rago A; Papa AA; Attena E; Parisi V; Golino P; Nigro G; Russo V
Cardiovasc Drugs Ther; 2021 Oct; 35(5):1003-1007. PubMed ID: 32946035
[TBL] [Abstract][Full Text] [Related]
34. Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial.
Cavallari I; Ruff CT; Nordio F; Deenadayalu N; Shi M; Lanz H; Rutman H; Mercuri MF; Antman EM; Braunwald E; Giugliano RP
Int J Cardiol; 2018 Apr; 257():102-107. PubMed ID: 29395361
[TBL] [Abstract][Full Text] [Related]
35. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial.
Nelson SE; Giugliano RP; Antman EM; Park JG; Norden AD; Rost NS; Silverman S; Singhal AB; Lanz HJ; Braunwald E; Ruff CT;
J Clin Neurosci; 2021 Apr; 86():294-300. PubMed ID: 33446422
[TBL] [Abstract][Full Text] [Related]
36. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.
Beyer-Westendorf J; Michalski F; Tittl L; Hauswald-Dörschel S; Marten S
Lancet Haematol; 2016 Oct; 3(10):e480-e488. PubMed ID: 27692306
[TBL] [Abstract][Full Text] [Related]
37. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.
Kirchhof P; Blank BF; Calvert M; Camm AJ; Chlouverakis G; Diener HC; Goette A; Huening A; Lip GYH; Simantirakis E; Vardas P
Am Heart J; 2017 Aug; 190():12-18. PubMed ID: 28760205
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery.
Fuji T; Fujita S; Kawai Y; Nakamura M; Kimura T; Kiuchi Y; Abe K; Tachibana S
Thromb Res; 2014 Jun; 133(6):1016-22. PubMed ID: 24680549
[TBL] [Abstract][Full Text] [Related]
39. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E
Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226
[TBL] [Abstract][Full Text] [Related]
40. Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.
Steffel J; Ruff CT; Yin O; Braunwald E; Park JG; Murphy SA; Connolly S; Antman EM; Giugliano RP
J Am Coll Cardiol; 2021 Mar; 77(9):1197-1207. PubMed ID: 33663737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
